| Literature DB >> 25279190 |
Gabriela Herrmann Cibeira1, Juliana Giacomazzi2, Ernestina Aguiar3, Silvana Schneider3, Betina Ettrich4, Caroline Isoppo DE Souza4, Suzi Camey5, Maira Caleffi6, Bernardete Weber7, Patricia Ashton-Prolla8, Emilio Hideyuki Moriguchi9.
Abstract
The purpose of this study was to evaluate the association between apolipoprotein E (APOE) allelic frequency, serum lipoproteins and breast cancer (BC). We conducted a nested case-control study within a cohort including 47 cases and 165 controls. Polymerase chain reaction-restriction fragment length polymorphism analyses of the APOE polymorphism were performed. In general, participants with the genotype including alleles e2 and e3 tended to have lower serum triglycerides, total cholesterol and low-density lipoprotein cholesterol levels and higher high-density lipoprotein (HDL) cholesterol levels compared to participants homozygous for the e3 allele and participants heterozygous for the e3 and e4 alleles, respectively. BC patients exhibited higher mean levels of total serum cholesterol (P=0.070), dietary fat intake (P=0.020) and dietary cholesterol intake (P=0.017) compared to control subjects. The allelic distribution between the two groups revealed that the presence of the e2 allele was positively associated with the absence of BC, whereas the e4 allele was positively associated with the BC case group (P=0.019). The distribution of the APOE genotypes was not significantly different between cases and controls (P=0.172). The concomitant presence of the e2 and e4 alleles was positively associated with the absence of BC and e4/e4 homozygosity was positively associated with BC (P=0.021). Our findings suggested that APOE polymorphism plays an important role in the development of BC, particularly when associated with higher serum triglyceride levels.Entities:
Keywords: apolipoprotein E; apolipoprotein E4; cardiovascular diseases; dyslipidemias; e4 allele
Year: 2014 PMID: 25279190 PMCID: PMC4179805 DOI: 10.3892/mco.2014.369
Source DB: PubMed Journal: Mol Clin Oncol ISSN: 2049-9450